Abisko Cayman Ltd. (2256)

Overview

Abbisko Cayman Limited stands as a pioneering entity in the arena of biopharmaceutical innovations, with its primary focus rooted in the clinical-stage development of novel small molecule oncology therapies targeted at the Mainland China market. With its inception in 2016 and headquartering in Shanghai, the People's Republic of China, Abbisko Cayman Limited has quickly ascended as a key player in the precision oncology and immuno-oncology therapeutic areas thanks to its dedication to discovering and developing ground-breaking small molecule therapies. Additionally, the company is actively engaged in various research and development endeavors across the biomedical and biotechnology landscape, further complemented by its offer of technical consultation services. Highlighting its collaborative spirit and dedication to advancing cancer therapy, Abbisko has entered strategic partnership agreements with industry giants such as Eli Lilly and Company for joint molecule discovery, development, and commercialization endeavors, as well as with BeiGene, Ltd. particularly focusing on the combination therapy of fexagratinib with tislelizumab for the treatment of urothelial cancer bearing specific genetic alterations.

Products and Services

• Small Molecule Precision Oncology Therapies

  Abbisko specializes in the development of small molecule drugs aimed at precision oncology, a field that tailors cancer treatment based on the genetic alterations of cancer cells. These therapies embody the company's commitment to leveraging cutting-edge science for the creation of more effective and targeted cancer treatments.

• Small Molecule Immuno-Oncology Therapies

  In the immuno-oncology therapeutic area, Abbisko focuses on small molecule treatments designed to harness the body's immune system in fighting cancer. This innovative approach seeks to develop therapies that improve patient outcomes by boosting the immune response against cancer cells.

• Biomedical and Biotechnology Research and Development

  Apart from its core focus on oncology therapies, Abbisko is heavily involved in broader research and development activities within the biomedical and biotechnology sectors. This facet of their operation highlights the company’s dedication to advancing scientific discovery and innovation across the healthcare spectrum.

• Technical and Technical Consultation Services

  Abbisko extends its expertise beyond product development to offer technical and consultation services. This offering enables the company to leverage its extensive knowledge in drug development and biotechnology to support other organizations within the industry, fostering a collaborative environment for innovation.

• Collaborative Agreements

  Noteworthy is Abbisko’s collaborative efforts with Eli Lilly and Company, and BeiGene, Ltd., which underscore the company's strategic approach to innovation through partnerships. These collaborations aim to accelerate the development and commercialization of novel molecules, including the promising combination therapy targeting specific genetic alterations in urothelial cancer, thereby enhancing the therapeutic landscape for cancer patients.